Corbus Pharmaceuticals Holdings financials
$6.63−4.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $881.7K | $3.9M | $36.1M | $4.8M | $2.4M | $1.9M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $881.7K | $3.9M | $36.1M | $4.8M | $2.4M | $1.9M |
| Gross margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$85.3M | -$48.7M | -$45.1M | -$39.8M | -$56.0M | -$122.8M | -$77.1M | -$56.7M | -$32.6M | -$20.0M |
| Net income | -$78.5M | -$40.2M | -$44.6M | -$42.3M | -$45.6M | -$111.3M | -$71.5M | -$55.7M | -$32.4M | -$20.0M |
| Net margin | — | — | — | — | −5176.4% | −2826.1% | −197.7% | −1154.5% | −1328.6% | −1046.3% |
| Diluted EPS | $-5.90 | $-3.68 | $-10.31 | $-10.15 | $-11.15 | $-42.60 | $-33.60 | $-29.40 | $-19.50 | $-14.70 |
| EBITDA | -$85.1M | -$48.1M | -$44.4M | -$34.1M | -$53.7M | -$121.7M | -$75.9M | -$56.3M | -$32.3M | -$19.9M |
| Operating cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.5M | -$48.2M | -$99.9M | -$45.7M | -$30.1M | -$27.8M | -$13.6M |
| Free cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.6M | -$48.2M | -$100.4M | -$48.5M | -$32.4M | -$28.5M | -$13.9M |
| Diluted shares | 13.3M | 10.9M | 4.3M | 4.2M | 4.1M | 2.6M | 2.1M | 1.9M | 1.7M | 1.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.5M | $17.2M | $13.7M | $17.0M | $25.0M | $85.4M |
| Short-term investments | $134.8M | $131.9M | $7.2M | $42.2M | $72.6M | $0.00 |
| Total debt | $0.00 | $0.00 | $16.2M | $19.1M | $19.5M | $18.7M |
| Total assets | $168.2M | $155.9M | $28.3M | $66.3M | $107.7M | $102.3M |
| Total liabilities | $20.7M | $13.5M | $35.2M | $33.3M | $38.6M | $57.0M |
| Shareholders' equity | $147.5M | $142.4M | -$6.9M | $33.0M | $69.1M | $45.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology